206 related articles for article (PubMed ID: 34213912)
1. Enhancing the Antitumor Effect of Doxorubicin with Photosensitive Metal-Organic Framework Nanoparticles against Breast Cancer.
Jiang Q; Zhang M; Sun Q; Yin D; Xuan Z; Yang Y
Mol Pharm; 2021 Aug; 18(8):3026-3036. PubMed ID: 34213912
[TBL] [Abstract][Full Text] [Related]
2. Porphyrin-based covalent organic frameworks as doxorubicin delivery system for chemo-photodynamic synergistic therapy of tumors.
Chen P; Li Y; Dai Y; Wang Z; Zhou Y; Wang Y; Li G
Photodiagnosis Photodyn Ther; 2024 Apr; 46():104063. PubMed ID: 38527660
[TBL] [Abstract][Full Text] [Related]
3. One-Pot Fabrication of Hollow Porphyrinic MOF Nanoparticles with Ultrahigh Drug Loading toward Controlled Delivery and Synergistic Cancer Therapy.
Sun X; He G; Xiong C; Wang C; Lian X; Hu L; Li Z; Dalgarno SJ; Yang YW; Tian J
ACS Appl Mater Interfaces; 2021 Jan; 13(3):3679-3693. PubMed ID: 33464038
[TBL] [Abstract][Full Text] [Related]
4. pH-Responsive metal-organic framework encapsulated gold nanoclusters with modulated release to enhance photodynamic therapy/chemotherapy in breast cancer.
Zhang L; Gao Y; Sun S; Li Z; Wu A; Zeng L
J Mater Chem B; 2020 Feb; 8(8):1739-1747. PubMed ID: 32030386
[TBL] [Abstract][Full Text] [Related]
5. Cascade-amplifying synergistic effects of chemo-photodynamic therapy using ROS-responsive polymeric nanocarriers.
Sun CY; Cao Z; Zhang XJ; Sun R; Yu CS; Yang X
Theranostics; 2018; 8(11):2939-2953. PubMed ID: 29896295
[TBL] [Abstract][Full Text] [Related]
6. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
7. Chitosan Immobilization on Bio-MOF Nanostructures: A Biocompatible pH-Responsive Nanocarrier for Doxorubicin Release on MCF-7 Cell Lines of Human Breast Cancer.
Abazari R; Mahjoub AR; Ataei F; Morsali A; Carpenter-Warren CL; Mehdizadeh K; Slawin AMZ
Inorg Chem; 2018 Nov; 57(21):13364-13379. PubMed ID: 30351060
[TBL] [Abstract][Full Text] [Related]
8. Cu (II)-porphyrin metal-organic framework/graphene oxide: synthesis, characterization, and application as a pH-responsive drug carrier for breast cancer treatment.
Gharehdaghi Z; Rahimi R; Naghib SM; Molaabasi F
J Biol Inorg Chem; 2021 Sep; 26(6):689-704. PubMed ID: 34420089
[TBL] [Abstract][Full Text] [Related]
9. Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity.
Mazzucchelli S; Bellini M; Fiandra L; Truffi M; Rizzuto MA; Sorrentino L; Longhi E; Nebuloni M; Prosperi D; Corsi F
Oncotarget; 2017 Jan; 8(5):8383-8396. PubMed ID: 28039473
[TBL] [Abstract][Full Text] [Related]
10. Ultra-thin metal-organic framework nanosheets for chemo-photodynamic synergistic therapy.
Zeng R; He T; Lu L; Li K; Luo Z; Cai K
J Mater Chem B; 2021 May; 9(20):4143-4153. PubMed ID: 33973611
[TBL] [Abstract][Full Text] [Related]
11. Nano-delivery vehicle based on chlorin E6, photodynamic therapy, doxorubicin chemotherapy provides targeted treatment of HER-2 negative, ανβ3-positive breast cancer.
He Z; Jiang H; Zhang X; Zhang H; Cui Z; Sun L; Li H; Qian J; Ma J; Huang J
Pharmacol Res; 2020 Oct; 160():105184. PubMed ID: 32946931
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-loaded nanoscale metal-organic framework for tumor-targeting combined chemotherapy and chemodynamic therapy.
Xue T; Xu C; Wang Y; Wang Y; Tian H; Zhang Y
Biomater Sci; 2019 Nov; 7(11):4615-4623. PubMed ID: 31441464
[TBL] [Abstract][Full Text] [Related]
13. PEGylated hydrazided gold nanorods for pH-triggered chemo/photodynamic/photothermal triple therapy of breast cancer.
Xu W; Qian J; Hou G; Wang Y; Wang J; Sun T; Ji L; Suo A; Yao Y
Acta Biomater; 2018 Dec; 82():171-183. PubMed ID: 30336271
[TBL] [Abstract][Full Text] [Related]
14. Actively targeting D-α-tocopheryl polyethylene glycol 1000 succinate-poly(lactic acid) nanoparticles as vesicles for chemo-photodynamic combination therapy of doxorubicin-resistant breast cancer.
Jiang D; Gao X; Kang T; Feng X; Yao J; Yang M; Jing Y; Zhu Q; Feng J; Chen J
Nanoscale; 2016 Feb; 8(5):3100-18. PubMed ID: 26785758
[TBL] [Abstract][Full Text] [Related]
15. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid.
Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F
Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317
[TBL] [Abstract][Full Text] [Related]
16. A new NIR-triggered doxorubicin and photosensitizer indocyanine green co-delivery system for enhanced multidrug resistant cancer treatment through simultaneous chemo/photothermal/photodynamic therapy.
Yu Y; Zhang Z; Wang Y; Zhu H; Li F; Shen Y; Guo S
Acta Biomater; 2017 Sep; 59():170-180. PubMed ID: 28629893
[TBL] [Abstract][Full Text] [Related]
17. Self-assembly of porphyrin-grafted lipid into nanoparticles encapsulating doxorubicin for synergistic chemo-photodynamic therapy and fluorescence imaging.
Hameed S; Bhattarai P; Liang X; Zhang N; Xu Y; Chen M; Dai Z
Theranostics; 2018; 8(19):5501-5518. PubMed ID: 30555560
[TBL] [Abstract][Full Text] [Related]
18. All-Trans Retinoic Acid and Doxorubicin Delivery by Folic Acid Modified Polymeric Micelles for the Modulation of Pin1-Mediated DOX-Induced Breast Cancer Stemness and Metastasis.
Liu Y; Yu F; Dai S; Meng T; Zhu Y; Qiu G; Wen L; Zhou X; Yuan H; Hu F
Mol Pharm; 2021 Nov; 18(11):3966-3978. PubMed ID: 34579532
[TBL] [Abstract][Full Text] [Related]
19. pH-Sensitive mesoporous silica nanoparticles for chemo-photodynamic combination therapy.
Yan T; Cheng J; Liu Z; Cheng F; Wei X; He J
Colloids Surf B Biointerfaces; 2018 Jan; 161():442-448. PubMed ID: 29121617
[TBL] [Abstract][Full Text] [Related]
20. Polymeric micelles encapsulating pH-responsive doxorubicin prodrug and glutathione-activated zinc(II) phthalocyanine for combined chemotherapy and photodynamic therapy.
Gao D; Lo PC
J Control Release; 2018 Jul; 282():46-61. PubMed ID: 29673646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
